#immune checkpoint inhibitors

All articles tagged with "immune checkpoint inhibitors"

A Cell study developed a diet-based mouse model of checkpoint-inhibitor adverse events.
Diet and gut microbiome composition influenced the severity of inflammation in mice.
Switching off a protein in fragile immune cells reversed inflammation in the model.

DT Editorial Team·Oct 22, 2026·via medicalxpress.com

The International Neoadjuvant Melanoma Consortium published an updated pooled analysis in Nature Medicine on 1 October 2026.
The analysis covers three-year and five-year survival plus other outcome data for 1,038 melanoma patients treated with neoadjuvant therapy.
Neoadjuvant immune checkpoint inhibitors are already standard of care for resectable stage IIIB–D melanoma.
Authors state that knowledge gaps remain regarding optimal treatment type and long-term survival determinants.

DT Editorial Team·Oct 1, 2026·via nature.com

A nationwide, population-based analysis published in Nature Medicine on 10 September 2026 examines COVID-19 mRNA vaccination around the start of immune checkpoint inhibitor (ICI) therapy in patients with cancer.
The abstract summary states that both pre-ICI and post-ICI COVID-19 mRNA vaccinations were associated with outcomes detailed in the full paper.
The study design uses the ICI start date to compare vaccination before versus after treatment initiation, drawing on linked population-level data.
Observational cohorts of this kind broaden evidence for immunocompromised patients but carry caveats such as confounding by indication and immortal time bias.

DT Editorial Team·Sep 11, 2026·via nature.com